Going Concern Warning, CEO Gains Control via Preferred Shares, and Reverse Stock Split Highlight Severe Financial Distress
GCAN has more than doubled off its 52-week low of $0.036 on light trading volume (0.2× avg).
Summary
Greater Cannabis Company, Inc. filed its annual 10-K, disclosing substantial doubt about its ability to continue as a going concern, a 1-for-1,500 reverse stock split, and the CEO gaining 51% voting control through newly issued Series B Preferred Shares for waived compensation, amidst zero revenue and material internal control weaknesses.
Key Events · Legal and Risk Events · GCAN
-
Going Concern Warning Issued
Management disclosed 'substantial doubt' about the company's ability to continue as a going concern through March 2027, citing limited cash ($815), significant current liabilities ($742,464), recurring losses, and negative operating cash flows.
-
Severe Financial Distress
The company reported zero revenue for both 2025 and 2024, with a net loss of $(331,612) in 2025, an increase from $(179,041) in 2024. Cash on hand is critically low at $815.
-
1-for-1,500 Reverse Stock Split Effected
A reverse stock split was implemented on October 16, 2025, reducing outstanding common shares from approximately 1.35 billion to 900,256.
-
CEO Gains Voting Control via Preferred Shares
CEO Aitan Zacharin received 1,000 Series B Convertible Preferred Shares in October 2025 for waiving $20,000 in accrued compensation, granting him 51.0% of the total voting power.
Analysis · GCAN · Life Sciences
The company's annual 10-K reveals a critical financial situation, with management explicitly stating 'substantial doubt' about its ability to continue as a going concern due to minimal cash reserves ($815), significant current liabilities ($742,464), and recurring losses with no revenue. A 1-for-1,500 reverse stock split was implemented in October 2025, a measure often indicative of severe financial distress for micro-cap companies. Furthermore, the CEO, Aitan Zacharin, was granted 51% voting control through the issuance of 1,000 Series B Convertible Preferred Shares in exchange for waiving $20,000 in accrued compensation, a significant governance change. The filing also highlights material weaknesses in internal control over financial reporting, stemming from inadequate segregation of duties and the absence of an audit committee with a financial expert. These factors collectively paint a highly negative picture of the company's operational and financial health, signaling extreme risk for investors.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCAN was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $234.3K. The 52-week trading range was $0.04 to $3.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.